Chrysophanol suppresses growth and metastasis of T cell acute lymphoblastic leukemia via miR-9/PD-L1 axis
T cell acute lymphoblastic leukemia (T-ALL) was a malignant lymphoma. Therefore, the development of novel therapeutic agents against T-ALL is imperative. Previous studies have shown that chrysophanol (CHL), an anthraquinone compound isolated from the Rheum palmatum L., exerts anti-proliferative and anti-metastatic effects in multiple malignant tumors. However, the effect of CHL on the progression of TALL is poorly understood. The aim of this study was to explore the role of CHL in the biological behavior of T-ALL cells and determine its underlying mechanism. Both T-ALL cell lines (Jurkat and TALL-104) were treated with CHL. The proliferation, apoptosis, migration, and invasion of T-ALL cells were determined by CCK-8, flow cytometry, wound healing, and Transwell assay, respectively. Western blot and RT-qPCR were applied to examine gene expression. The dual-luciferase reporter gene assay was employed to examine the regulation mechanism of miR-9 and PD-L1. A T-ALL xenograft model also was used to examine the effect of CHL on the tumor growth and metastasis in vivo. CHL treatment significantly inhibited the proliferation, migration, and invasion ability of both Jurkat and TALL-104 cells and induced cell apoptosis and the expression of miR-9. Moreover, miR-9 was proved to target PD-L1 by binding to its 3′-untranslated region (UTR). Mechanically, pretreated with PD-L1 inhibitor could augment the anti-proliferation and anti-metastatic effect of CHL, while miR-9-silenced alleviated this effect. Consistent with in vitro studies, CHL significantly suppressed the growth and metastasis of tumor in vivo. Our finding uncovers the antitumorigenic effect of CHL in T-ALL progression through upregulating the expression of miR-9 and suppressing PD-L1 expression, which may provide a new potential strategy for T-ALL clinical treatment.
KeywordsT cell acute lymphoblastic leukemia Chrysophanol miR-9 PD-L1 Growth and metastasis
Qingsong Yin and Xudong Wei provided the fund and designed the project.
Junjie Yin performed the experiences and wrote the paper.
Bo Liang and Ruihua Mi performed the experiences.
Hao Ai and Lin Chen collected and analyzed the data.
The study was funded by the Natural Science Foundation of China (No. 81170520).
Compliance with ethical standards
Conflict of interest
The authors declare no competing interests.
- Abdul Wahid SF, Ismail NA, Mohd-Idris MR, Jamaluddin FW, Tumian N, Sze-Wei EY, Muhammad N, Nai ML (2014) Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev 23:2535–2552PubMedPubMedCentralGoogle Scholar
- Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ (2019) Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia 33:132–147PubMedGoogle Scholar
- Ashizawa M, Okayama H, Ishigame T, Thar Min AK, Saito K, Ujiie D, Murakami Y, Kikuchi T, Nakayama Y, Noda M, Tada T, Endo H, Fujita S, Sakamoto W, Saito M, Saze Z, Momma T, Ohki S, Mimura K, Kono K (2019) miRNA-148a-3p regulates immunosuppression in DNA mismatch repair-deficient colorectal Cancer by targeting PD-L1. Mol Cancer Res 17:1403–1413PubMedGoogle Scholar
- Bai J, Wu J, Tang R, Sun C, Ji J, Yin Z, Ma G, Yang W (2019). Emodin, a natural anthraquinone, suppresses liver cancer in vitro and in vivo by regulating VEGFR2 and miR-34a. Investig New DrugsGoogle Scholar
- Deng M, Xue YJ, Xu LR, Wang QW, Wei J, Ke XQ, Wang JC, Chen XD (2019) Chrysophanol suppresses hypoxia-induced epithelial-Mesenchymal transition in colorectal Cancer cells. Anat Rec (Hoboken) 302:1561–1570Google Scholar
- Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A (2016) Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the acute leukemia working Party of the European Society for blood and marrow transplantation. Cancer 122:2941–2951PubMedGoogle Scholar
- Kloten V, Lampignano R, Krahn T, Schlange T (2019) Circulating tumor cell PD-L1 expression as biomarker for therapeutic efficacy of immune checkpoint inhibition in NSCLC. Cells 8Google Scholar
- Lee JS, Ruppin E (2019). Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1. JAMA OncolGoogle Scholar
- Liu J, Fan L, Yu H, Zhang J, He Y, Feng D, Wang F, Li X, Liu Q, Li Y, Guo Z, Gao B, Wei W, Wang H, Sun G (2019a) Endoplasmic reticulum stress causes liver Cancer cells to release exosomal miR-23a-3p and up-regulate programmed death ligand 1 expression in macrophages. Hepatology 70:241–258PubMedGoogle Scholar
- McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM, Cocco L, Ratti S, Martelli AM, Laidler P, Dulinska-Litewka J, Rakus D, Gizak A, Lombardi P, Nicoletti F, Candido S, Libra M, Montalto G, Cervello M (2017) Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs. Aging (Albany NY) 9:1477–1536Google Scholar
- Mulder TA, Wahlin BE, Osterborg A, Palma M (2019) Targeting the immune microenvironment in lymphomas of B-cell origin: from biology to clinical application. Cancers (Basel) 11Google Scholar
- Orso F, Quirico L, Dettori D, Coppo R, Virga F, Ferreira LC, Paoletti C, Baruffaldi D, Penna E, Taverna D (2019) Role of miRNAs in tumor and endothelial cell interactions during tumor progression. Semin Cancer BiolGoogle Scholar
- Otter SJ, Chatterjee J, Stewart AJ, Michael A (2019) The role of biomarkers for the prediction of response to checkpoint immunotherapy and the rationale for the use of checkpoint immunotherapy in cervical Cancer. Clin Oncol (R Coll Radiol)Google Scholar
- Refae S, Gal J, Ebran N, Otto J, Borchiellini D, Peyrade F, Chamorey E, Brest P, Milano G, Saada-Bouzid E (2019) Germinal immunogenetics predict treatment outcome for PD-1/PD-L1 checkpoint inhibitors. Investig New DrugsGoogle Scholar
- Richardsen E, Andersen S, Al-Saad S, Rakaee M, Nordby Y, Pedersen MI, Ness N, Ingebriktsen LM, Fassina A, Tasken KA, Mills IG, Donnem T, Bremnes RM, Busund LT (2019) Low expression of miR-424-3p is highly correlated with clinical failure in prostate Cancer. Sci Rep 9:10662PubMedPubMedCentralGoogle Scholar
- Roolf C, Saleweski JN, Stein A, Richter A, Maletzki C, Sekora A, Escobar HM, Wu XF, Beller M, Junghanss C (2019). Novel isoquinolinamine and isoindoloquinazolinone compounds exhibit antiproliferative activity in acute lymphoblastic leukemia cells. Biomol Ther (Seoul): 492–501Google Scholar
- Setti Boubaker N, Cicchillitti L, Said R, Gurtner A, Ayed H, Blel A, Karray O, Essid MA, Gharbi M, Bouzouita A, Rammeh Rommeni S, Chebil M, Piaggio G, Ouerhani S (2019) The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer. Mol Biol RepGoogle Scholar
- Touat M, Maisonobe T, Knauss S, Ben Hadj Salem O, Hervier B, Aure K, Szwebel TA, Kramkimel N, Lethrosne C, Bruch JF, Laly P, Cadranel J, Weiss N, Behin A, Allenbach Y, Benveniste O, Lenglet T, Psimaras D, Stenzel W, Leonard-Louis S (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985–e994PubMedGoogle Scholar
- Yang XY, Sheng Y (2019) MiR-101 represses T-cell acute lymphoblastic leukemia by targeting CXCR7/STAT3 axis. Oncol ResGoogle Scholar
- Zhai B, Zhang N, Han X, Li Q, Zhang M, Chen X, Li G, Zhang R, Chen P, Wang W, Li C, Xiang Y, Liu S, Duan T, Lou J, Xie T, Sui X (2019) Molecular targets of beta-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: a review. Biomed Pharmacother 114:108812PubMedGoogle Scholar